Are melanocortin receptors present in the brain?

Yes — MC3R and MC4R are expressed centrally, which is why the same family that governs pigmentation also participates in energy balance.

Why does delayed treatment matter?

Many interventions protect in animal ischaemia models when given prophylactically; few retain effect when delayed, and real injuries are not anticipated.

Does this literature apply to Semax?

Only as family context. Semax replaces positions 8 to 10, which are part of the receptor-binding core these studies concern.

Semax (ACTH Fragment Peptide)

What the Melanocortin Neuroprotection Literature Reports

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A body of work has examined melanocortin peptides in models of neural injury. Catania reviewed neuroprotective actions of melanocortins in Trends in Neurosciences in 2008, and Giuliani and colleagues examined MC4R-stimulating melanocortins in cerebral ischaemia models in Endocrinology in 2006.

Key facts

Catania 2008: Trends Neurosci review (PMID 18550183)
Giuliani 2006: Endocrinology (PMID 16254026)
Receptor implicated: MC4R
Model: Cerebral ischaemia, in animals
Notable design feature: Early and delayed treatment compared
Human evidence: Not established

Why melanocortins were examined in the brain at all

Melanocortin receptors are not confined to skin and adrenal tissue. MC3R and MC4R are expressed centrally, which is why the same receptor family that governs pigmentation also participates in energy balance. Central expression makes neural effects a coherent hypothesis rather than a stretch.

What the 2006 work examined

Giuliani and colleagues compared both early and delayed treatment with MC4R-stimulating melanocortins in cerebral ischaemia. Testing delayed as well as early administration is the more demanding design — an intervention that only works if given before or immediately at injury has limited relevance, since real injuries are not anticipated.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Why the delayed arm is the informative one

Many interventions protect tissue in animal ischaemia models when given prophylactically. Very few retain effect when administration is delayed, and that gap is a major reason neuroprotection findings have translated poorly from animals to humans. A study reporting both is testing the harder and more relevant question.

What the review contributed

Catania described neuroprotective actions of melanocortins as a therapeutic opportunity in Trends in Neurosciences in 2008. A review in a journal of that kind indicates the field considered the finding worth surveying — and the word opportunity conveys the stage accurately, then and arguably now.

Why this connects to Semax without transferring to it

Semax derives from the same precursor region, so this literature is context for the family. But Semax replaces positions 8 to 10 with Pro-Gly-Pro, and those replaced residues are part of the melanocortin receptor-binding core that MT-2 is built around. A compound that discards the receptor core is not straightforwardly described by findings about receptor-stimulating melanocortins.

What is not being claimed

Anything about neuroprotection in any person. This is animal model literature and a review of it, reported as what was measured and in what model. Semax holds no marketing authorisation from the MHRA, EMA or FDA and is supplied here for laboratory research only.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Are melanocortin receptors present in the brain?: Yes — MC3R and MC4R are expressed centrally, which is why the same family that governs pigmentation also participates in energy balance.
Why does delayed treatment matter?: Many interventions protect in animal ischaemia models when given prophylactically; few retain effect when delayed, and real injuries are not anticipated.
Does this literature apply to Semax?: Only as family context. Semax replaces positions 8 to 10, which are part of the receptor-binding core these studies concern.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum